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Drug resistant tuberculosis continues to increase and new approaches for its treatment
are necessary. The identification of M. tuberculosis clinical isolates presenting efflux
as part of their resistant phenotype has a major impact in tuberculosis treatment.
In this work, we used a checkerboard procedure combined with the tetrazolium
microplate-based assay (TEMA) to study single combinations between antituberculosis
drugs and efflux inhibitors (EIs) against multidrug resistantM. tuberculosis clinical isolates
using the fully susceptible strain H37Rv as reference. Efflux activity was studied on a
real-time basis by a fluorometric method that uses ethidium bromide as efflux substrate.
Quantification of efflux pump genes mRNA transcriptional levels were performed by
RT-qPCR. The fractional inhibitory concentrations (FIC) indicated synergistic activity for
the interactions between isoniazid, rifampicin, amikacin, ofloxacin, and ethidium bromide
plus the EIs verapamil, thioridazine and chlorpromazine. The FICs ranged from 0.25,
indicating a four-fold reduction on the MICs, to 0.015, 64-fold reduction. The detection
of active efflux by real-time fluorometry showed that all strains presented intrinsic efflux
activity that contributes to the overall resistance which can be inhibited in the presence of
the EIs. The quantification of themRNA levels of themost important efflux pump genes on
these strains shows that they are intrinsically predisposed to expel toxic compounds as
the exposure to subinhibitory concentrations of antibiotics were not necessary to increase
the pump mRNA levels when compared with the non-exposed counterpart. The results
obtained in this study confirm that the intrinsic efflux activity contributes to the overall
resistance in multidrug resistant clinical isolates of M. tuberculosis and that the inhibition
of efflux pumps by the EIs can enhance the clinical effect of antibiotics that are their
substrates.
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Introduction
Tuberculosis (TB) remains a public health issue worldwide
(World Health Organization, 2014). According to the World
Health Organization (2013) there were an estimated 9.0 million
tuberculosis cases and 480,000 people developed multidrug-
resistant tuberculosis (MDR-TB). Among these there were an
estimated 210,000 deaths (World Health Organization, 2014).
The TB control is severely complicated by the emergence of
multi- and extensively drug resistantMycobacterium tuberculosis
strains. Multidrug resistant M. tuberculosis is recognized as M.
tuberculosis strains resistant to at least isoniazid and rifampicin,
and extensively drug resistant (XDR) M. tuberculosis as those
resistant to isoniazid, rifampicin, a fluoroquinolone and one
of the three second line injectables: amikacin, kanamycin, or
capreomycin (World Health Organization, 2008).M. tuberculosis
strains that are resistant to isoniazid and rifampicin and either
a fluoroquinolone or an aminoglycoside, but not both, are
colloquially termed “pre-XDR-TB” strains.
Despite the known effectiveness of the antituberculosis
standard treatment against susceptible strains ofM. tuberculosis,
the first-line drugs isoniazid and rifampicin are ineffective
for treating patients infected with multidrug resistant strains.
Consequently, second-line drugs have to be employed. These
drugs are more toxic, poorly tolerated, and sometimes difficult
to obtain (Green and Garneau-Tsodikova, 2013). Furthermore,
extensively drug resistant M. tuberculosis strains easily emerge
during second-line treatment due to poor tolerance and lack of
compliance (World Health Organization, 2008). The emergence
and spread of resistant phenotypes of M. tuberculosis are
nowadays a major health problem due to the reduced therapeutic
options, high mortality rates and danger to the community if
transmission of the bacillus is not readily stopped (World Health
Organization, 2013).
Intrinsic resistance of M. tuberculosis to antimicrobial agents
is mainly attributed to the reduced permeability of the cell
wall due to the lipid-rich composition and the presence of
mycolic acids that considerably decreases the intracellular access
of antibiotics (Brennan and Nikaido, 1995). However, it cannot
prevent completely their entrance. Other intrinsic mechanisms
of resistance, such as eﬄux pumps, act synergistically with the
permeability barrier to reduce the passage of antimicrobials
across the bacterial cell wall (De Rossi et al., 2006; Piddock, 2006;
Li and Nikaido, 2009). Eﬄux pumps usually confer low levels
of drug resistance but play an important role in the evolution
to high levels of resistance in M. tuberculosis (Machado et al.,
2012). Prolonged exposure to subinhibitory concentrations of
antituberculosis drugs facilitate the progressive acquisition of
chromosomal mutations and provide the natural ground for the
development of bacteria with high-level resistance phenotypes
due to the acquisition of mutations in the antibiotic target. This
chain of events is particularly relevant in long-term therapies
such as that used in tuberculosis treatment, where a sustained
pressure of sub-inhibitory concentrations of antibiotics can
result in an increased eﬄux activity and allow the selection of
spontaneous high-level drug resistant mutants (Machado et al.,
2012; Schmalstieg et al., 2012).
A possible alternative to prevent the resistance generated by
eﬄux is the chemical inhibition of these systems by molecules
that act as inhibitors, the so called eﬄux inhibitors (EIs) that
can act as treatment adjuvants to increase the activity of the
antibiotics (Marquez, 2005). Such molecules are expected to
reduce the intrinsic resistance of the bacteria by increasing
the intracellular concentration of antibiotics even in highly
resistant strains and reduce the frequency of emergence of
resistant mutant strains (Mahamoud et al., 2007; Viveiros et al.,
2010). The net result of blocking the eﬄux of an antimicrobial
compound by the use of an EI is to decrease the threshold
concentration (i.e., the minimum inhibitory concentration,
MIC) of the antibiotic when the EI is used at concentrations
devoid of any antibacterial activity. Many compounds have
been reported as having inhibitory activity on mycobacterial
eﬄux systems such as calcium channel blockers like verapamil,
thioridazine, chlorpromazine, farnezol, reserpine, or uncouplers
of the proton motive force such as carbonyl cyanide m-
chlorophenyl hydrazone (CCCP) (Viveiros et al., 2012), but none
has evolved toward clinical usage.
So far no MDR clinical strain was identified with high-level
resistance attributed solely to overexpressed eﬄux pumps and the
contribution of these systems to the overall level of resistance in
MDR-TB clinical strains, irrespective of the existing mutations
for drug targets in the bacteria, has not been thoroughly explored.
In the present study we have explored the contribution of
the eﬄux mechanisms to the overall resistance to isoniazid,
rifampicin, amikacin and ofloxacin in five MDR (two of which
pre-XDR) M. tuberculosis clinical isolates from Brazil by (i) the
analysis of the synergistic effect of the EIs verapamil, thioridazine
and chlorpromazine on the MICs of the antibiotics and ethidium
bromide by a tetrazolium microplate-based assay (TEMA) on
checkerboard format; (ii) the analysis of real-time eﬄux activity,
using ethidium bromide as eﬄux substrate, by a semi-automated
fluorometric method in presence and absence of each EI; and
(iii) the analysis of mRNA transcriptional levels of selected eﬄux
pump genes in these strains.
Materials and Methods
M. tuberculosis Strains, Its Characterization, and
Selection Criteria
The M. tuberculosis strains included in this study were selected
from the culture collection of the Mycobacteria Laboratory
of Interdisciplinary Area of Biomedical Sciences, Núcleo de
Pesquisa em Microbiologia Médica (NUPEMM), Faculty of
Medicine, Federal University of Rio Grande, Brazil, and
Fundação Estadual de Produção e Pesquisa em Saúde no
Centro de Desenvolvimento Científico e Tecnológico. The strains
were previously characterized using the proportion method
on Löwenstein-Jensen for isoniazid, rifampicin, amikacin, and
ofloxacin, and DNA sequencing to search for mutations
associated with resistance (data not shown) (Maschmann et al.,
2013). The strains to be studied were chosen based upon their
resistance to isoniazid, rifampicin, amikacin and ofloxacin and
presence of the most common mutations found in clinical
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isolates. The sampling comprises five multidrug resistant strains
(three resistant to isoniazid and rifampicin; one resistant to
isoniazid, rifampicin and amikacin; one resistant to isoniazid,
rifampicin and ofloxacin—the two latest colloquially considered
pre-XDR), whose phenotypic and genotypic characterization
is shown in Table 1. The M. tuberculosis H37Rv ATCC27294
reference strain was used as control.
Antimicrobials, Efflux Inhibitors, and Ethidium
Bromide
Isoniazid, rifampicin, ofloxacin, amikacin, chlorpromazine,
thioridazine, verapamil, ethidium bromide, glucose, phosphate
buffered solution (PBS), and 3-4,5-dimethylthiazol-2-yl-2,
5-diphenyl tetrazolium bromide (MTT) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Verapamil,
chlorpromazine, thioridazine, isoniazid, amikacin, and ethidium
bromide were prepared in sterile distilled water; rifampicin
was prepared in dimethyl sulfoxide (DMSO), and ofloxacin in
1% hydroxide chloride in water. Stock solutions were stored
at −20◦C. The work solutions were prepared at the day of the
experiments. The 10X MTT stock solution was prepared in
ultrapure sterile water and used at 1:1 in 10% Tween 80 (v/v).
Determination of Minimum Inhibitory
Concentrations (MIC)
For the determination of the MICs of the antibiotics, EIs, and
the eﬄux substrate ethidium bromide, the strains were grown
in Middlebrook 7H9 (DIFCO, Madrid, Spain) plus 10% OADC
supplement (oleic acid/albumin/dextrose/catalase) (Becton and
Dickinson, Diagnostic Systems, Sparks, MD, USA) at 37◦C
until they reached an OD600 of 0.8. Afterwards, the inoculum
was prepared by diluting the bacterial cultures in 7H9/OADC
medium to a final density of approximately 105 cells/ml
(Eliopoulos and Moellering, 1996). The MICs were determined
by a TEMA (Caviedes et al., 2002) with slight modifications.
Briefly, aliquots of 0.1ml of inoculum were transferred to each
well of the plate that contained 0.1ml of each compound
at concentrations prepared from two-fold serial dilutions in
7H9/OADC medium. The concentration ranges used are shown
in Table S1 of the Supplementary data. Growth controls with no
drug and a sterility control were included in each plate assay. Two
hundred microliters of sterile deionized water was added to all
outer-perimeter wells of the 96-well plates to reduce evaporation
of the medium in the wells during the incubation. The inoculated
plates were sealed in plastic bags and incubated at 37◦C for 7
days. After this period, MTT was added to each well to a final
concentration of 2.5% and the plates incubated overnight. The
bacterial viability was registered for each well based on the MTT
color change. Here, the amount of color generated is directly
proportional to the number of viable cells and a precipitate of
cells stained black can be observed in the bottom of the well. The
MIC was defined as the lowest concentration of compound that
totally inhibited bacterial growth (Gomez-Flores et al., 1995). All
assays were carried out in triplicate.
Determination of Fractional Inhibitory
Concentration (FIC) and Modulation Factor (MF)
Two-dimensional broth microdilution checkerboard assay
(Eliopoulos and Moellering, 1996) combined with TEMA, was
performed to assess the effect of the EIs verapamil, thioridazine
and chlorpromazine in combination with isoniazid, rifampicin,
amikacin and ofloxacin against the M. tuberculosis strains. Two
hundred microliters of sterile deionized water was added to all
outer-perimeter wells of the plates to prevent evaporation of the
medium during the incubation. The plates were prepared by
dispensing the serially diluted antibiotic in the x-axis and the
inhibitors in the y-axis. The concentration range used for each
compound is shown in Table S2. Aliquots of 0.1ml of inoculum
were transferred to each well of the 96-well plate and incubated
at 37◦C. In all assays were included growth and sterility controls.
The inoculated plates were sealed in plastic bags and incubated
at 37◦C for 7 days and the results interpreted as described
above. The modulation factor (MF) was used to quantify the
effect of the inhibitors on the MIC of antibiotics and ethidium
bromide (Formula 1) (Gröblacher et al., 2012). The modulation
factor reflects the reduction of MIC values of a given antibiotic
in the presence of the eﬄux inhibitor and was considered to
be significant when MF ≥ 4 (four-fold reduction). The effect
of each eﬄux inhibitor on the activity of each antibiotic was
determined by means of fractional inhibitory concentration
(FIC) determination according to Formula 2. The FIC was
calculated only for the antibiotic as the concentration of the
eﬄux inhibitor to be used in each combination corresponds to
≤¼ of its MIC, which is considered to be devoid of antibacterial
TABLE 1 | Phenotypic and genotypic characterization of the M. tuberculosis strains.
Strain Phenotype Genotype
katG inhA rpoB gyrA rrs
FURG-1 MDR S315T Wt S531L Wt Wt
FURG-2 MDR S315T Wt S531L Wt Wt
FURG-3 MDR S315T Wt S531L Wt Wt
FURG-4 MDR S315T Wt D516Y A90V Wt
FURG-5 MDR D735A Wt S531L Wt A>G 1401
H37Rv Susceptible Wt Wt Wt Wt Wt
MDR, multidrug resistant; R, resistant; Wt, wild-type.
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activity. The FIC indexes were interpreted using the criteria
established by Pillai et al. (2005). However, since we are only
evaluating the individual FIC for the antibiotic and not the
sum of the FICs, or FIC index (6FICantibiotic), the results were
interpreted as follows: FIC ≤ 0.25, synergism; FIC > 0.25 < 2,
indifference and FIC ≥ 2, antagonism. As such, an individual
FIC of ≤ 0.25, indicative of a four-fold reduction, was assumed
as synergy. We considered FIC > 0.25 as indifferent activity due
to the inherent variability of the method (Odds, 2003). The FIC
for the combinations was classified as ND (non-determinable)
when the MICs of the compounds alone were greater than the
highest, less than, or equal to the lowest concentration tested
(Moody, 1992). For combinations that showed tendencies for
synergy, isobolograms were constructed, by plotting changes in
the MIC of antibiotics as a function of the EIs concentration,
using GraphPad Prism V5.01 software (La Jolla, USA). Synergy
is illustrated by a concave isobol and antagonism, by a convex
isobol. All assays were carried out in triplicate.
MF =
MICantiobiotic
MICcombination
Formula 1. Modulation factor (MF) determination.
MICantibiotic corresponds to the MIC of the antibiotic;
MICcombination corresponds to the MIC of the antibiotic in
the presence of eﬄux inhibitor.
FICantibiotic =
MICcombination
MICalone
Formula 2. Fractional inhibitory concentration (FIC)
determination. MICcombination corresponds to the MIC
determined in the presence of the antibiotic and the inhibitor;
MICalone corresponds to the MIC of the antibiotic alone.
Evaluation of Efflux Activity by Real-time
Fluorometry
The assessment of eﬄux activity on a real-time basis was
performed using a semi-automated fluorometric method, as
previously described (Viveiros et al., 2010; Machado et al.,
2012). The M. tuberculosis strains were grown in 10ml of
7H9/OADC with 0.05% Tween 80 at 37◦C until they reach an
OD600 of 0.8. For the accumulation assays, the cultures were
centrifuged at 3500 rpm for 3min, the supernatant discarded
and the pellet washed in PBS. The OD600 was adjusted to 0.8
with PBS. In order to determine the concentration of ethidium
bromide that establish the equilibrium between eﬄux and influx,
aliquots of 0.05ml of the bacterial suspension were added to
0.2ml microtubes containing 0.05ml different concentrations
of ethidium bromide that ranged from 0.625 to 3µg/ml
with and without 0.4% glucose. The assays were conducted
at 37◦C in a Rotor-Gene 3000™ (Corbett Research, Sydney,
Australia), using the 530 nm band-pass and the 585 nm high-pass
filters as the excitation and detection wavelengths, respectively.
Fluorescence data was acquired every 60 s for 60min. The
selected concentration of ethidium bromide was further used
for the evaluation of the capacity of the EIs to retain ethidium
bromide inside the cells. The EIs verapamil, thioridazine and
chlorpromazine were tested at ½ MIC with and without 0.4%
glucose and ethidium bromide at the equilibrium concentration
determined for each strain and the assays performed like
described above. The inhibitory activity of the compounds was
determined by the calculation the relative final fluorescence
(RFF) value according to Formula 3 (Machado et al., 2011):
RFF =
RFtreated − RFuntreated
RFuntreated
Formula 3. Relative final fluorescence (RFF) determination.
RFtreated corresponds to the relative fluorescence at the last time
point of EtBr accumulation curve (minute 60) in the presence
of an inhibitor; and the RFuntreated corresponds to the relative
fluorescence at the last time point of the EtBr accumulation curve
of the untreated control tube. EtBr, ethidium bromide.
For the eﬄux assays, strains were exposed to conditions
that promote maximum accumulation of ethidium bromide, i.e.,
ethidium bromide equilibrium concentration for each strain, no
glucose, presence of the eﬄux inhibitor that caused maximum
accumulation (in all cases verapamil), and incubation at 25◦C
for 1 h (Viveiros et al., 2010). Before incubation, the cultures
were centrifuged at 3500 rpm for 3min, resuspended in PBS,
centrifuged again and OD600 adjusted to 0.4. The suspension
was incubated with ethidium bromide and verapamil under the
conditions described above. Aliquots of 0.05ml of cells were
transferred to 0.2ml microtubes containing 0.05ml of each eﬄux
inhibitor at ½ MIC without ethidium bromide. Control tubes
with only cells and cells with and without 0.4% glucose were
included. Fluorescence was measured in the Rotor-Gene™ 3000
and data was acquired every 30 s for 30min. Eﬄux activity was
quantified by comparing the fluorescence data obtained under
conditions that promote eﬄux (presence of glucose and absence
of eﬄux inhibitor) with the data from the control in which the
mycobacteria are under conditions of no eﬄux (presence of an
inhibitor and no energy source). Thus, the relative fluorescence
corresponds to the ratio of fluorescence that remains per unit of
time, relatively to the ethidium bromide-loaded cells.
RNA Isolation, RT-qPCR, and Quantification of
Efflux Pump mRNA Levels
Total RNA from M. tuberculosis cultures was extracted using
the RNeasy Mini kit (QIAGEN, GmbH, Hilden, Germany) as
previously described (Machado et al., 2012). The concentration
and quality of total RNA was measured using a NanoDrop
1000 spectrophotometer (Thermo Scientific, Waltham, USA).
The primers sequences used for the analysis of the eﬄux
genes mmpL7, mmr, Rv1258c, p55, Rv2469, efpA, and the
transcriptional regulator whiB7 are described in Table 2. The
RT-qPCR assay was performed in a Rotor-Gene™ 3000
thermocycler and followed the protocol recommended for use
with the QuantiTect SYBR Green RT-PCR Kit (QIAGEN) with
the following amplification program: reverse transcription for
30min at 50◦C; initial activation step for 15min at 95◦C; 35
cycles of denaturation at 94◦C for 30 s, annealing at 52◦C for
30 s and extension at 72◦C for 30 s; a final extension step at
72◦C for 5min; and an additional step at 50◦C for 15 s followed
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TABLE 2 | Primers used in this study.
Gene Primer Sequence (5′-3′) Amplification
product (bp)
References
16S_Fw CAA GGC TAA AAC TCA AAG GA 197 Rodrigues
et al., 201216S_Rv GGA CTT AAC CCA ACA TCT CA
mmpL7_Fw TAC CCA AGC TGG AAA CAA 214
mmpL7_Rv CCG TCA GAA TAG AGG AAC CAG
p55_Fw AGT GGG AAA TAA GCC AGT AA 198
p55_Rv TGG TTG ATG TCG AGC TGT
efpA_Fw ATG GTA ATG CCT GAC ATC C 131
efpA_Rv CTA CGG GAA ACC AAC AAA G
mmr_Fw AAC CAG CCT GCT CAA AAG 221
mmr_Rv CAA CCA CCT TCA TCA CAG A
Rv1258c_Fw AGT TAT AGA TCG GCT GGA TG 268
Rv1258c_Rv GTG CTG TTC CCG AAA TAC
Rv2459_Fw CAT CTT CAT GGT GTT CGT G 232 Machado
et al., 2012Rv2459_Rv CGG TAG CAC ACA GAC AAT AG
whiB7_Fw TCG AGG TAG CCA AGA CAC T 109 Machado,
2014whiB7_Rv TCG AAT ATC TCA CCA CCC CA
Fw, forward; Rv, reverse.
by melt analysis (50–99◦C). The quantification of the relative
mRNA levels of the genes in the strains exposed and non-
exposed to subinhibitory concentrations of the antibiotics was
performed using the standard curve method (Bustin, 2000).
Standards consisted of known numbers of molecules prepared
from cDNA PCR products of the target genes. The PCR products
were purified by gel extraction (QIAquick Gel Extraction Kit,
QIAGEN), quantified by spectrophotometry and the molecular
weight determined. The number of molecules/µl of the standards
was calculated according to the following Formula 4 (Yin et al.,
2001):
molecules/µl =
6.023× 1023 × C × OD260
MW
Formula 4. Quantification of mRNA copy number. In this
formula, C corresponds to 50 ng/µl for DNA and MW, to the
molecular weight of the target gene.
To generate the standard curve, each RNA sample was
successively diluted in nuclease-free water, the Ct-values of each
dilution measured in triplicate, plotted against the logarithm
of their initial template copy numbers and the R2 obtained to
evaluate the performance of the assay. The PCR amplification
efficiency was controlled by the slope of the standard curve. To
compensate variations in the input RNA and efficiency of the
reverse transcription step, the results were normalized against the
M. tuberculosis 16S rDNA reference gene. Data is presented as the
n-fold difference relative to the control (non-exposed condition
or, when necessary, the reference strain) plus standard deviation
(±SD).
Results
Evaluation of the Synergistic Effect between
Efflux Inhibitors and Antibiotics
The MICs of the antibiotics isoniazid, rifampicin, amikacin and
ofloxacin, the eﬄux substrate ethidium bromide, as well as the
MICs of the EIs verapamil, thioridazine, and chlorpromazine,
for each of the strains enrolled in this study, are given in Table 3.
The FICs and MF obtained for each combination are listed in
Table 4. All the multidrug resistant strains (n = 5) presented
high-level resistance to isoniazid (5/5) and high- (4/5) and
intermediate-level resistance to rifampicin (1/5). High-level
resistance to ofloxacin was observed in one multidrug resistant
strain, FURG-4. Resistance to amikacin (high-level) was detected
only in one multidrug resistant strain, FURG-5. A mutation
associated with the resistant phenotype was identified in all five
multidrug resistant strains (Table 1). The combination between
the antibiotics and the EIs tested at ½ of its MIC consistently
produced non-determinable FICs since the combination
interaction was always bellow the concentration range tested
(see Tables S1, S2). This data indicates that the effect of these
compounds at ½ of MIC, as commonly tested in the literature
and in previous works of our group (Viveiros et al., 2010), is due
to its antibacterial effect and not due exclusively to the inhibition
of eﬄux activity (Machado, 2014). As such, for a more accurate
and precise analysis of the effect of the EIs on the MIC values of
the antibiotics and eﬄux substrate, the results were compared
at ¼ MIC of each eﬄux inhibitor, where all the FICs (for all the
strains) are inside the concentration range tested (Tables 3, 4).
As can be seen in Table 4, the MIC values of isoniazid
were reduced (MF ≥ 3) in 2/5 multidrug resistant strains
(FURG-1 and -2) by the three inhibitors, and in 1/5 only by
chlorpromazine (FURG-4). For this last strain, the FIC result
indicated a synergist effect. For strain FURG-5, none of the
inhibitors was able to reduce the high-level resistance to isoniazid
(MIC of 512µg/ml). For H37Rv, the MIC for isoniazid was
reduced by all the inhibitors originating a FIC of 0.25 indicative
of synergism. Concerning rifampicin resistance, the MIC values
were reduced with verapamil in all rifampicin resistant strains
by four-fold (2/5), eight-fold (1/5), 32-fold (1/5), and 64-fold
(1/5). Thioridazine was able to reduce the MIC of rifampicin in
2/5 strains and chlorpromazine in 1/5. Of note, strain FURG-
4, which displays intermediate level of resistance to rifampicin
and harbors a rare mutation on codon 516, was the strain for
which the resistance to rifampicin was reduced in the presence
of the three inhibitors to levels similar of that of the susceptible
H37Rv reference strain (Table 4). The MIC for rifampicin of the
susceptible H37Rv reference strain was reduced four-fold only by
verapamil. Resistance to amikacin was found in strain FURG-5 to
which the MIC was reduced four-fold with chlorpromazine. For
the amikacin susceptible strains the MIC values were reduced by
two- to four-fold depending on the strain. Resistance to ofloxacin
was reduced only in strain FURG-2 by four-fold with verapamil
and thioridazine. Concerning ethidium bromide, the MIC values
were reduced in all strains with verapamil by four- to 16-fold,
and with thioridazine and chlorpromazine by four- to eight-fold
in 4/6 and 2/6 strains, respectively. The FICs determined for the
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TABLE 3 | Minimum inhibitory concentrations of the antibiotics, efflux inhibitors, and ethidium bromide for the M. tuberculosis strains.
Strain MIC (µg/ml)
INH RIF AMK OFX VP TZ CPZ EtBr
FURG-1 10 2048 2 1 512 15 15 8
FURG-2 10 1024 2 2 512 15 30 8
FURG-3 5 1024 1 1 512 15 15 4
FURG-4 5 16 2 16 512 15 30 4
FURG-5 512 1024 640 1 512 15 30 8
H37Rv 0.1 0.5 2 2 512 15 15 4
INH, isoniazid; RIF, rifampicin; AMK, amikacin; OFX, ofloxacin; VP, verapamil; TZ, thioridazine; CPZ, chlorpromazine; EtBr, ethidium bromide.
TABLE 4 | Synergistic activity of the efflux inhibitors in combination with antituberculosis drugs against the M. tuberculosis strains.
Antibiotics EIs Strains
FURG-1 FURG-2 FURG-3 FURG-4 FURG-5 H37Rv
MIC
(µg/ml)
FIC MF MIC
(µg/ml)
FIC MF MIC
(µg/ml)
FIC MF MIC
(µg/ml)
FIC MF MIC
(µg/ml)
FIC MF MIC
(µg/ml)
FIC MF
INH No EI 10 - - 10 - - 5 - - 5 - - 512 - - 0.1 - -
+VP ¼ 3 0.3 3 3 0.3 3 3 0.6 2 5 1 1 512 1 1 0.025 0.25 4
+TZ ¼ 3 0.3 3 3 0.3 3 3 0.6 2 5 1 1 512 1 1 0.025 0.25 4
+CPZ ¼ 3 0.3 3 3 0.3 3 3 0.6 2 1.25 0.25 4 512 1 1 0.025 0.25 4
RIF No EI 2048 - - 1024 - - 1024 - - 16 - - 1024 - - 0.5 - -
+VP ¼ 512 0.25 4 256 0.25 4 16 0.015 64 0.5 0.03 32 128 0.125 8 0.125 0.25 4
+TZ ¼ 2048 1 1 512 0.5 2 32 0.03 32 1 0.06 16 1024 1 1 0.25 0.5 2
+CPZ ¼ 2048 1 1 512 0.5 2 512 0.5 2 0.5 0.03 32 1024 1 1 0.25 0.5 2
OFX No EI 1 - - 2 - - 1 - - 16 - - 1 - - 2 - -
+VP ¼ 0.5 0.5 2 0.5 0.25 4 0.5 0.5 2 16 1 1 0.5 0.5 2 1 0.5 2
+TZ ¼ 1 1 1 0.5 0.25 4 0.5 0.5 2 16 1 1 0.5 0.5 2 1 0.5 2
+CPZ ¼ 0.5 0.5 2 1 0.5 2 0.5 0.5 2 16 1 1 0.5 0.5 2 1 0.5 2
AMK No EI 2 - - 2 - - 1 - - 2 - - 640 - - 2 - -
+VP ¼ 0.5 0.25 4 0.5 0.25 4 0.25 0.25 4 0.5 0.25 4 640 1 1 0.5 0.125 4
+TZ ¼ 1 0.5 2 0.5 0.25 4 0.25 0.25 4 0.5 0.25 4 640 1 1 1 0.5 2
+CPZ ¼ 1 0.5 2 0.25 0.125 4 0.5 0.5 2 0.5 0.25 4 160 0.25 4 0.5 0.125 4
EtBr No EI 8 - - 8 - - 4 - - 4 - - 8 - - 4 - -
+VP ¼ 1 0.125 8 0.5 0.06 16 0.25 0.0625 16 1 0.25 4 0.5 0.06 4 0.5 0.125 8
+TZ ¼ 2 0.25 4 2 0.25 4 0.5 0.125 8 2 0.5 2 1 0.125 8 2 0.5 2
+CPZ ¼ 8 1 1 8 1 1 4 1 1 1 0.25 4 2 0.25 4 4 1 1
MIC, Minimum inhibitory concentration; FIC, fractional inhibitory concentration; MF, modulation factor; INH, isoniazid; RIF, rifampicin; AMK, amikacin; OFX, ofloxacin; VP, verapamil; TZ,
thioridazine; CPZ, chlorpromazine; EtBr, ethidium bromide; EI, efflux inhibitor. Values in bold type indicate synergistic interactions.
individual synergistic interactions described above ranged from
0.25 (MF = 4) to 0.015 (MF = 64) (Table 4) and is illustrated
in Figure 1 for the four antibiotics and ethidium bromide plus
verapamil againstM. tuberculosis FURG-4 as an example for the
remaining strains tested. Noteworthy, no antagonistic interaction
was observed in this study.
Assessment of Efflux Activity by Real-time
Fluorometry
After determining the synergistic effect between the inhibitors
and antibiotics, the inhibitors were evaluated for their ability
to inhibit eﬄux activity by the M. tuberculosis strains in study.
Real-time fluorometry was applied to study their behavior in the
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FIGURE 1 | Synergic effect of the combination of amikacin,
rifampicin, isoniazid, ofloxacin and ethidium bromide, plus
verapamil. In the figure is represented the isobolograms for the
M. tuberculosis strain FURG-4 as an example. The dashed line represents
the hypothetical indifferent effect. The concave isobol observed represents
the synergic effect.
presence of the broad eﬄux substrate ethidium bromide with
and without glucose as the source of metabolic energy. First,
was determined the lowest concentration that causes minimal
accumulation of ethidium bromide, i.e., the concentration
for which there is an equilibrium between influx and eﬄux
of the substrate. The lowest concentration that resulted in
equilibrium between the influx and eﬄux of ethidium bromide
was 0.25µg/ml for the reference strain H37Rv, 0.5µg/ml for
strains FURG-2 to FURG-5, and 1µg/ml for strain FURG-1.
These results clearly indicate that the clinical drug resistant M.
tuberculosis strains can handle higher concentrations of ethidium
bromide than the reference strain, which is suggestive of the
presence of more active eﬄux systems in these strains. After
this, the EIs under study were tested under the equilibrium
concentration of ethidium bromide identified for each strain.
In Figure 2A, we can observe the effect of the EIs on the
accumulation of ethidium bromide by M. tuberculosis FURG-
5, in the presence of glucose, as an example. Due to the
large number of graphs describing the effects of verapamil,
thioridazine and chlorpromazine, with and without glucose, on
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FIGURE 2 | Effect of the efflux inhibitors on the accumulation (A)
and efflux (B) of ethidium bromide at 0.5µg/ml by M.
tuberculosis FURG-5, as an example. Assays were performed at
37◦C in the presence of glucose. Concentrations of verapamil (VP),
thioridazine (TZ), chlorpromazine (CPZ) are at ½ their MIC (Table 3).
EtBr, ethidium bromide.
TABLE 5 | Relative final fluorescence (RFF) based on accumulation of EtBr.
Strains RFF of the efflux inhibitors
Verapamil Thioridazine Chlorpromazine
− glucose + glucose − glucose + glucose − glucose + glucose
FURG-1 0.82 0.47 0.66 0.29 0.32 0.01
FURG-2 1.36 1.01 0.63 0.33 0.39 0.21
FURG-3 0.71 0.53 0.21 0.27 0.07 −0.04
FURG-4 1.58 1.22 0.76 0.45 0.64 0.46
FURG-5 1.62 1.48 1.37 1.54 1.06 1.01
H37Rv 1.57 2.27 0.77 1.31 0.52 0.88
Accumulation of EtBr at 0.25µg/ml (H37Rv), 0.5µg/ml (FURG-2 to 5), and 1µg/ml (FURG-1), in the presence of glucose at 0.4%. The most efficient inhibitors are in bold type.
the eﬄux activity of the other fiveM. tuberculosis strains studied,
the RFF indexes were calculated and the results presented in
tabular form (Table 5). The index of activity of the three EIs
tested against the M. tuberculosis strains was calculated with
the aid of the Formula 3 (see Material and Methods). The RFF
index is a measure of how effective the compound is on the
inhibition of ethidium bromide eﬄux (at a given non-inhibitory
concentration) by comparison of the final fluorescence at the last
time point (60min) of the treated cells with the cells treated only
with ethidium bromide. The inhibitor that presents the highest
ethidium bromide accumulation rate was verapamil, followed
by thioridazine and chlorpromazine, as previously demonstrated
(Machado et al., 2012; Rodrigues et al., 2012). The results showed
that all strains studied presented with eﬄux activity which can
be inhibited in the presence of the EIs (Figure 2B as an example
of the results obtained with all strains tested). Eﬄux activity
was more pronounced in the clinical strain FURG-5 (Figure 2B);
strains FURG-1 to - 4 presented significant and similar EtBr
eﬄux activities but less than FURG-5, whilst H37Rv presented a
basal eﬄux activity, assessed by the semi-automated fluorometric
method (data not shown). Moreover, it was also noticed that the
accumulation of ethidium bromide by theM. tuberculosis strains
is not affected by the presence of glucose (Table 5), revealing
that the external energization of M. tuberculosis cells is not
determinant to guarantee an optimal active eﬄux, as previously
noticed (Machado et al., 2012; Rodrigues et al., 2012). These
results provide further evidence that eﬄux activity is an intrinsic
characteristic of susceptible and drug resistant M. tuberculosis
strains and is directly involved in antibiotic resistance in the
M. tuberculosis clinical strains, irrespectively of the presence or
absence of mutations that confer antibiotic resistance.
Quantification of Efflux Pump mRNA by RT-qPCR
To further analyze the contribution of eﬄux pumps to antibiotic
resistance in these strains, six eﬄux pump genes, mmpl7,
mmr, p55, Rv1258c, Rv2459 and efpA, and the transcriptional
regulator whib7, were selected to examine changes in mRNA
transcriptional levels (Table 2). The quantification of eﬄux pump
mRNA level of the M. tuberculosis clinical isolates is shown in
Table 6. When comparing the mRNA levels of each eﬄux pump
gene for each isolate with that of the H37Rv reference strain,
no increase in the expression of these genes was detected in
these strains, with the exception of strain FURG-1. This strain
presents a two- to five-fold increase in mRNA levels for all genes
tested (Figure 3). To analyze if the presence of an antibiotic could
induce an increase in mRNA transcriptional levels, the strains
were exposed to ½ of the respective MIC of the antibiotic to
which the strains was shown to be resistant and the transcription
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TABLE 6 | Relative quantification of efflux pump gene mRNA quantity in the M. tuberculosis strains exposed to antibiotics.
Strain Condition Relative mRNA gene quantity (±SD) of:
mmpl7 mmr Rv1258c p55 efpA Rv2459 whib7
Non-exposed 1.0 1.0 1.0 1.0 1.0 1.0 1.0
FURG-1
+INH 0.01±0.00 0.05±0.01 0.02± 0.00 0.01± 0.00 0.07±0.00 0.01± 0.00 0.02± 0.00
+RIF 0.02±0.00 0.04±0.01 0.01± 0.00 0.03± 0.00 0.01±0.00 0.01± 0.00 0.01± 0.00
FURG-2
+INH 94.56 ± 1.64 137.21 ± 0.00 20.09 ± 1.05 24.65 ± 2.56 10.41 ± 3.16 0.41± 0.39 2.35 ± 0.16
+RIF 172.05 ± 10.42 249.20 ± 12.95 90.18 ± 15.08 84.90 ± 5.14 56.80 ± 2.95 16.59 ± 4.19 13.08 ± 1.13
FURG-3
+INH 0.23±0.03 0.16±0.02 0.03± 0.01 0.18± 0.04 0.80±0.29 0.13± 0.01 0.04± 0.00
+RIF 0.02±0.00 0.05±0.00 0.01± 0.00 0.06± 0.03 0.06±0.04 0.05± 0.00 0.06± 0.03
FURG-4
+INH 0.28±0.05 0.17±0.01 0.22± 0.01 0.53± 0.11 0.76±0.03 0.37± 0.03 0.42± 0.06
+RIF 0.01±0.00 0.03±0.00 0.05± 0.00 0.01± 0.00 0.02±0.00 0.01± 0.00 0.01± 0.00
+OFX 4.45 ± 0.15 2.41 ± 0.25 2.75 ± 0.29 4.17 ± 0.29 4.02 ± 0.14 2.96 ± 0.51 5.51 ± 0.38
FURG-5
+INH 1.00±0.10 0.60±0.24 0.10± 0.06 0.76± 0.05 1.15 ± 0.04 0.48± 0.03 0.20± 0.01
+RIF 0.07±0.04 0.01±0.01 0.01± 0.00 0.01± 0.01 0.02±0.00 0.02± 0.00 0.01± 0.00
+AMK 0.01±0.00 0.08±0.02 0.02± 0.00 0.01± 0.00 0.01±0.00 0.01± 0.00 0.01± 0.00
INH, isoniazid; RIF, rifampicin; OFX, ofloxacin; AMK, amikacin. Data is presented as the n-fold difference relative to the control (non-exposed condition) plus standard deviation (±SD).
Values in bold type were considered to be overexpression.
FIGURE 3 | Quantification of the mRNA transcriptional levels (n-fold)
for the efflux pump genes in strain FURG-1. The mRNA levels of the
genes mmpl7, mmr, p55, Rv1258c, Rv2459, efpA and the transcriptional
regulator whib7 were compared with the H37Rv reference strain.
levels determined against the non-exposed counterpart. The
results are presented in Table 6. Increased mRNA levels were
found in strains FURG-2 for all seven genes upon exposure to
rifampicin, and six genes for isoniazid (Table 6). Strain FURG-4
demonstrates increased mRNA levels for all genes tested upon
exposure to ofloxacin. Strain FURG-5 shows only a marginal
increase in the expression of the efpA gene. Concerning strains
FURG-1, FURG-3, FURG-4, and FURG-5 it was noticed a
general decrease in the transcript numbers of all eﬄux pump
genes after the exposure to isoniazid, rifampicin, or amikacin.
Discussion
Understanding themechanism by whichM. tuberculosis develops
resistance and how this can be reduced is essential to shorten
and improve tuberculosis treatment. Mutations in the genes
related with antibiotic resistance and eﬄux of drugs have been
shown to contribute to the development of drug resistance in
M. tuberculosis (Louw et al., 2011; Silva and Palomino, 2011;
Machado et al., 2012). In this work, we aimed first to determine
whether the combination of antituberculosis drugs and putative
EIs act synergistically against a panel of drug resistant M.
tuberculosis strains, and second to study the contribution of eﬄux
systems to the overall drug resistance in these strains.
We applied a two-dimensional checkerboard procedure
combined with a TEMA to evaluate the interactions of first and
second line drugs and the eﬄux substrate ethidium bromide
with the EIs verapamil, thioridazine, and chlorpromazine against
a panel MDR M. tuberculosis clinical strains. The results
showed a synergistic interaction between all antituberculosis
drugs and the EIs although with different degrees of synergism
(Figure 1 as an example and Table 4). The interaction between
rifampicin, amikacin or ethidium bromide plus the inhibitors
was significant even at low concentrations of the inhibitors,
whereas, for isoniazid and ofloxacin the synergic interaction
was observed only at higher concentrations of the inhibitors.
Significant reduction of the MIC values of ofloxacin was
achieved only in one susceptible strain and no reduction was
observed in the ofloxacin-resistant strain. This result indicates
that, although fluoroquinolones are considered to be common
substrates eﬄux pumps in other bacterial pathogens (Costa
et al., 2011), eﬄux activity seems to have little contribution
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for ofloxacin resistance in multidrug resistant M. tuberculosis
strains, as previously shown (Machado, 2014). Resistance to
isoniazid was only moderately reduced, as these isoniazid
resistant strains harbor mutations within the katG gene (Table 1)
associated with high-level resistance (Böttger, 2011; Cambau
et al., 2015). Strain FURG-5 presents a rare mutation in the
katG gene, D735A (Wei et al., 2003), and the highest level of
isoniazid resistance. Although rifampicin is not assumed to be
a common substrate of eﬄux pumps, it was possible to reduce
rifampicin MICs for all mutant strains by at least one of the
EIs. Although we cannot assume reversal of resistance due to
the absence of breakpoints for this methodology, the rifampicin
MIC values for strain FURG-4 reached values similar to the
fully susceptible reference strain H37Rv, despite the presence
of a mutation. The mutation D516Y in rpoB gene has been
described by others as been associated with different levels of
susceptibility, from sensitive to high-level resistance (Williams
et al., 1998; Somoskovi et al., 2006; Cambau et al., 2015).
Resistance to amikacin was reduced by at least one of the
inhibitors in drug susceptible strains. Concerning the amikacin-
resistant strain, the resistance was reduced by four-fold with
chlorpromazine. Kigondu et al. (2014) have recently reported
that combinations between chlorpromazine and aminoglycosides
results in synergic activity against Mycobacterium smegmatis. In
this study, verapamil was the eﬄux inhibitor that demonstrated
stronger activity against these strains which are in accordance
with previous reports (Rodrigues et al., 2009, 2011, 2012; Louw
et al., 2011; Machado et al., 2012; Gupta et al., 2013). Moreover,
the results demonstrated that these EIs are active against both
antibiotic-susceptible and -resistant strains indicating that the
effect of these compounds is not dependent of the mutational
profile of the strain. Additionally, it is likely these inhibitors have
a wide range of activity acting on several eﬄux systems instead of
been specific of a particular eﬄux pump.
In order to correlate the data obtained by the MICs
determination and eﬄux activity, we applied a semi-automated
fluorometric method using ethidium bromide as an indicator of
eﬄux activity. The accumulation of increasing concentrations
of ethidium bromide by the M. tuberculosis clinical strains,
when comparing with the pan-susceptible H37Rv strain, clearly
demonstrated that the clinical drug resistant strains, except
FURG-3, possess enhanced eﬄux activity which could be
inhibited in the presence of the EIs verapamil, thioridazine and
only marginally by chlorpromazine (Table 5). We have recently
observed the same kind of results with multi- and extensively
drug resistantM. tuberculosis strains (Machado, 2014).
For the analysis of eﬄux pump gene expression, we first
compared the mRNA levels of the clinical strains with the
antibiotic susceptible reference strain,M. tuberculosisH37Rv.We
observed an increase in the mRNA levels of all eﬄux genes tested
in strain FURG-1 when compared with the reference strain.
Regarding the remaining strains no eﬄux pump gene was found
to be overexpressed using the H37Rv strain as a reference. As
such, the clinical strains were exposed to ½ of the MIC of the
antibiotics and the corresponding mRNA levels were compared
with those of the same strain grown in a drug-free condition.
We noticed an increase in the mRNA levels of almost all genes in
strains FURG-2 exposed to isoniazid and rifampicin and FURG-4
exposed to ofloxacin.We also observed that the strains expressing
eﬄux pumps shown the expression of the whole panel of genes
tested and not a particular gene, as previously shown (Machado
et al., 2012; Rodrigues et al., 2012; Machado, 2014). These results
showed that these clinical strains are prepared to expel toxic
compounds possibly as a consequence of the constant pressure
to which they were subjected in the clinical setting (Costa
et al., 2011; Machado et al., 2012). We did not notice a straight
correlation between the eﬄux pump gene expression and the
reduction of the antibiotic resistance levels by the EIs. Although
the effect demonstrated by the EIs on the resistance levels of the
antibiotics combined with the results obtained with the real-time
fluorometry clearly supports the involvement of eﬄux pumps
in the overall resistance in these strains, it does not necessarily
indicate eﬄux pump over expression. All strains presented high-
level resistance to the antibiotics tested (Table 3) due to the
presence of a mutation conferring resistance (Table 1) coupled
with a component of eﬄux demonstrated by the reduction of
the resistance levels with the inhibitors (Table 4). The extent of
the later will depend on the resistance level conferred by the
mutation plus the different environmental pressures to which
the strain was exposed. It is expected that clinical strains do not
need to increase the amount of eﬄux pumps in the membrane
to survive when exposed to subinhibitory concentrations of the
antibiotics to which they are resistant. Additionally, we notice
that some genes were downregulated upon exposure to the
antibiotics (Table 6). At the present we do not know the reason,
although we can hypothesize that (i) gene downregulation occurs
due to an antibiotic killing effect, or (ii) the downregulation of
these eﬄux systems occurs at the expense of the overproduction
of other unknown eﬄux systems or (iii) gene downregulation
can be due to the presence of mutations in the genes encoding
the eﬄux pumps. Further experiments would be necessary to test
these hypotheses.
Tuberculosis continues to be a deadly disease worldwide and
new approaches for its treatment are necessary. The identification
of clinical isolates of M. tuberculosis that presented an eﬄux
component as part of their resistant phenotype has a major
impact in tuberculosis therapeutics as well in the development
of new drugs. With the increase of multi- and extensively
drug resistant strains, there are few alternatives available to
treat these patients. The data presented evidences a possible
therapeutic value for compounds that have the ability to inhibit
mycobacterial eﬄux pumps via the retention of co-administered
antimycobacterial drugs that are subject to eﬄux (Viveiros et al.,
2012). The rationale and procedures used in this study proved
to be useful to evaluate the presence of active eﬄux systems
in drug resistant M. tuberculosis strains. In our hands, they
afford quantitative and reproducible results and proved to be
an inexpensive, rapid, high-throughput assay to predict the
activity of EIs against drug susceptible and resistant strains ofM.
tuberculosis. In conclusion, this study strengths the notion that
intrinsic eﬄux activity also contributes to the overall resistance
in drug resistant clinical isolates of M. tuberculosis bearing the
most frequent mutations for resistance and that the inhibition
of this eﬄux activity by compounds such as thioridazine and
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verapamil can promote the clinical effect of the antibiotics that
are subject to eﬄux, highlighting the urgent need of animal
studies to guide the future progress of these compounds into
combinational clinical trials (Viveiros et al., 2012; Gupta et al.,
2013; Dutta and Karakousis, 2014).
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